Peroxitech Therapeutics Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Location

Philadelphia PA US

Primary Industry

Biotechnology

About

Based in Pennsylvania, US, and founded by Aron Fisher, Sheldon I. Feinstein, and Thomas Han (CEO), Peroxitech Inc., doing business as Peroxitech Therapeutics is a biopharmaceutical company that develops PIP-2 to repair and reverse acute lung injury (ALI) by addressing the cytokine storm cascade pathway. In May 2021, Peroxitech Therapeutics raised Seed funding led by investor Xontogeny, LCC. The company creates biopharmaceuticals based on its lead molecule, PIP-2, which helps to reduce reactive oxygen species (ROS) buildup in the lungs resulting from respiratory failure with hypoxemia and tissue acidosis, as well as to treat acute lung injury. The company intends to use the May 2021 funding to advance the new treatment of acute lung injury and additional toxicology preclinical trials.

Current Investors

Xontogeny, LLC, Perceptive Advisors

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.peroxitech.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.